TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 173 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 1.37 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $147,608 | -23.1% | 16,511 | +32.0% | 0.00% | 0.0% |
| Q2 2023 | $192,061 | -30.6% | 12,504 | +1.6% | 0.00% | 0.0% |
| Q1 2023 | $276,874 | +39.6% | 12,311 | +30.5% | 0.00% | 0.0% |
| Q4 2022 | $198,355 | +7.2% | 9,432 | +25.7% | 0.00% | 0.0% |
| Q3 2022 | $185,000 | +1.6% | 7,504 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $182,000 | -26.9% | 7,504 | -22.4% | 0.00% | 0.0% |
| Q1 2022 | $249,000 | -25.0% | 9,673 | -9.5% | 0.00% | -50.0% |
| Q4 2021 | $332,000 | +78.5% | 10,686 | +39.1% | 0.00% | +100.0% |
| Q3 2021 | $186,000 | +66.1% | 7,680 | +0.1% | 0.00% | 0.0% |
| Q2 2021 | $112,000 | -40.7% | 7,676 | +1.2% | 0.00% | 0.0% |
| Q1 2021 | $189,000 | -10.4% | 7,587 | -1.9% | 0.00% | 0.0% |
| Q4 2020 | $211,000 | – | 7,734 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 895,821 | $8,008,640 | 3.99% |
| Deep Track Capital, LP | 7,370,000 | $65,887,800 | 2.54% |
| VR Adviser, LLC | 2,623,677 | $23,455,672 | 2.47% |
| Sio Capital Management, LLC | 884,770 | $7,909,844 | 2.45% |
| Kynam Capital Management, LP | 957,502 | $8,560,068 | 1.40% |
| MPM BioImpact LLC | 552,846 | $4,942,443 | 1.32% |
| ARMISTICE CAPITAL, LLC | 7,500,000 | $67,050,000 | 1.03% |
| Parkman Healthcare Partners LLC | 577,494 | $5,162,796 | 0.95% |
| Tri Locum Partners LP | 251,702 | $2,250,216 | 0.72% |
| Cheyne Capital Management (UK) LLP | 26,200 | $234,228 | 0.68% |